Drugs / ILS-920
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00827190 | Feb → Jul 2009 | ischemic stroke | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ILS-920 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00827190 ↗ |
| Known as | WAY-265920 | ChEMBL registry synonym — accepted as the source's own label CHEMBL508360 ↗ |
| Modality | Small molecule | — CHEMBL508360 ↗ |
| Route | Intravenous | “administered intravenously” NCT00827190 ↗ |